Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell

Chalk River Isotope Reactor Decommissioning Date Set

Canadian Nuclear Safety Commission renewed Canadian Nuclear Laboratories’ operating license for the Chalk River isotope reactor

The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Laboratories’ (CNL) Nuclear Research and Test Establishment Operating License for the Chalk River Laboratories (CRL) site. as of 2016, it was the world’s largest production reactor for medical nuclear imaging isotopes. However, the decision includes a plan to transition to shutdown and preparation for decommissioning by 2028.  

The decision followed a public hearing Jan. 23–25, 2018. The new license will be valid from April 1, 2018 until March 31, 2028.

CRL is the largest single science and technology complex in Canada, located near Chalk River, Ontario, about 160 km northwest of Ottawa. The National Research Universal (NRU) reactor at Chalk River has been operating at CRL since 1957. Until Oct. 31, 2016, the reactor produced a large percentage of the world's medical isotopes, used in both the diagnosis and treatment of life-threatening diseases. In late 2016, it ended production of molybdenum-99 (Mo-99), the precursor to the making of technetium-99m (Tc-99m), the most widely used radioisotope for single photon emission computed tomography (SPECT) imaging.

The 61-year-old nuclear reactor has had safety concerns requiring shutdowns to make repairs and updates over the past decade. Each time the reactor has shut down, there was a shortage of Tc-99m.  This has prompted the United States government to support plans to create a domestic supply of medical isotopes. In February 2018, the U.S. Food and Drug Administration (FDA) and the Nuclear Regulatory Commission (NRC) took steps to ensure a stable and secure supply of Tc-99m. The FDA approved the NorthStar Medical Radioisotopes' RadioGenix System used to produce Mo-99. 

Read the FDA approval article “FDA Clears Path for First Domestic Supply of Tc-99m Isotope.”

With the new Canadian reactor licensing agreement, CNL will present a mid-term update in 2023 on its licensed activities at CRL during a public commission meeting within the community. Members of the public will have the opportunity to intervene orally and in writing. CNSC staff will also report annually on CNL’s performance at CRL at a commission meeting with public participation.

The record of decision is available on request to the Commission Secretariat and will be posted on the CNSC website at nuclearsafety.gc.ca. 

For more information: https://www.canada.ca/en/nuclear-safety-commission/news/2018/03/canadian...

Related Content

NorthStar Medical Radioisotopes Completes Construction on Beloit, Wis. Molybdenum-99 Processing Facility
News | Radiopharmaceuticals and Tracers | July 16, 2019
NorthStar Medical Radioisotopes LLC  announced completion of construction on its 20,000-square-foot molybdenum-99 (Mo-...
Bracco Imaging Acquires Blue Earth Diagnostics
News | Radiopharmaceuticals and Tracers | July 01, 2019
Bracco Imaging S.p.A. has signed a definitive agreement to acquire Blue Earth Diagnostics, a molecular imaging company...

Image courtesy of Philips Healthcare

Feature | Molecular Imaging | July 01, 2019 | By Sharvari Rale
Diagnostic procedures have always been a cornerstone of early prognosis and patient triaging.
DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Information Technology | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
United Imaging Announces First U.S. Clinical Install of uMI 550 Digital PET/CT System
News | PET-CT | June 19, 2019
United Imaging announced the first U.S. clinical installation of the uMI 550 Digital positron emission tomography/...
International Working Group Releases New Multiple Myeloma Imaging Guidelines

X-ray images such as the one on the left fail to indicate many cases of advanced bone destruction caused by multiple myeloma, says the author of new guidelines on imaging for patients with myeloma and related disorders. Image courtesy of Roswell Park Comprehensive Cancer Center.

News | Computed Tomography (CT) | June 17, 2019
An International Myeloma Working Group (IMWG) has developed the first set of new recommendations in 10 years for...
A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse

Figure 1. A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse from Amsterdam Ph.D. researcher Gustav Strijkers.

News | Magnetic Resonance Imaging (MRI) | June 07, 2019
The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the best molecular...
BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...
Study Explores Magnetic Nanoparticles as Bimodal Imaging Agent for PET/MRI

Image courtesy of MR Solutions.

News | PET-MRI | May 23, 2019
Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...